Results 61 to 70 of about 3,775 (204)

Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub‐Types

Biotechnology and Bioengineering, Volume 123, Issue 2, Page 310-323, February 2026.
ABSTRACT Clostridioides difficile infection presents an escalating clinical challenge due to the proliferation of hypervirulent and antibiotic‐resistant strains. The primary symptoms of disease, namely colitis and diarrhea, are induced by the release of two toxins: TcdA and TcdB.
Carly M. Catella, Sudeep Sarma, Caroline M. Hinesley, Corey E. Febo, Keith A. Breau, Deniz Durmusoglu, Ethan Purnell, Scott T. Magness, Carol K. Hall, Stefano Menegatti, Nathan Crook   +10 more
wiley   +1 more source

Oral proton‐reprogrammed nanomedicine to break the inflammatory bowel disease‐Clostridium difficile infection vicious cycle

iMeta, Volume 5, Issue 1, February 2026.
Research on the mechanism of OPR restoring intestinal epithelial cell (IEC) structure and function in inflammatory bowel disease (IBD) treatment. (A) Schematic diagram of OPR structure and the rate of GP release under different conditions. (B) Schematic diagram of OPR targeting IBD colonic lesions through charge interaction.
Wensheng Chen, Yuntao Zhang, Jue Wang, Yiming Li, Hao Wu, Qiong Huang, Wei Wu, Kelong Ai   +7 more
wiley   +1 more source

Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 2, Page 276-287, January 2026.
In a large‐scale, multiple‐site Danish faecal microbiota transplantation (FMT) system, the cure rates in patients with Clostridioides difficile infection treated with encapsulated FMT were improved following exclusion of three low‐performing donors and implementation of a two‐dose FMT regimen.
Sara Ellegaard Paaske, Simon Mark Dahl Baunwall, Tone Rubak, Nina Rågård, Jens Kelsen, Mette Mejlby Hansen, Anders Bergh Lødrup, Søren Lyhne, Emilie Glavind, Christa Marie Culmback Fernis, Stine Hald, Lise Tornvig Erikstrup, Lars Vinter‐Jensen, Simon Lal, Susan Mikkelsen, Christian Erikstrup, Jens Frederik Dahlerup, Christian Lodberg Hvas   +17 more
wiley   +1 more source

Identification of Potential RBPJ-Specific Inhibitors for Blocking Notch Signaling in Breast Cancer Using a Drug Repurposing Strategy

Pharmaceuticals, 2022
Notch signaling is a key parameter in regulating cell fate during tissue homeostasis, and an aberrant Notch pathway can result in mammary gland carcinoma and has been associated with poor breast cancer diagnosis. Although inhibiting Notch signaling would
Mengjie Rui, Min Cai, Yu Zhou, Wen Zhang, Lianglai Gao, Ke Mi, Wei Ji, Dan Wang, Chunlai Feng   +8 more
doaj   +1 more source

Hypersensitivity Reactions Associated With Fidaxomicin Use [PDF]

Clinical Infectious Diseases, 2013
We report hypersensitivity reactions associated with fidaxomicin, an antibacterial drug approved for the treatment of Clostridium difficile-associated diarrhea. These reactions are viewed as significant because of severity and unexpected because fidaxomicin is minimally absorbed.
Dmitri E, Iarikov, John, Alexander, Sumathi, Nambiar   +2 more
openaire   +2 more sources

Gut Microbiome as a Source and Propagator of Multidrug‐Resistance: Mechanisms and Therapeutic Strategies

Advanced Gut &Microbiome Research, Volume 2026, Issue 1, 2026.
Human gut microbiome has risen as a critical nexus in the global landscape of antimicrobial resistance (AMR), acting both as a reservoir and a driver of multidrug‐resistant organisms (MDROs). This review explores the mechanistic foundations by which the gut microbiota contributes to resistance development, focusing on the acquisition and spread of ...
Meghana Shashikanth, D. B. M. Virupakshaiah, Jiong Yu   +2 more
wiley   +1 more source

A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection.

, 2023
20.500.12530/87857Background Clostridioides difficile infection (CDI) is a major cause of diarrhea in hospitalized adult patients. This study aims to evaluate the clinical characteristics, clinical cure, recurrence and mortality in patients with CDI ...
de Gea Grela, Alejandro, Martínez-Martín, Patricia, Jiménez-González, María, Marcelo, Cristina, Carrasco Molina, Sergio, Diaz-Pollan, Beatriz, Moreno Ramos, Francisco, Mora-Rillo, Marta   +7 more
core   +1 more source

Final Demonstration of the Co-Identity of Lipiarmycin A3 and Tiacumicin B (Fidaxomicin) through Single Crystal X-ray Analysis

Antibiotics, 2017
Lipiarmycin A3 and tiacumicin B possess the same chemical structure and have been considered identical till recently, when some authors have suggested the possibility of a minor difference between the chemical structures of the two antibiotics.
Stefano Serra, Luciana Malpezzi, Angelo Bedeschi, Claudio Fuganti, Piera Fonte   +4 more
doaj   +1 more source

Mechanistic Insights Into the Inhibition of Clostridioides difficile Binary Toxin by Indolylmethyl Glucosinolate and Indole‐3‐Carbinol

Scientifica, Volume 2026, Issue 1, 2026.
Clostridioides difficile infection (CDI) remains a significant healthcare challenge, primarily due to its toxin‐mediated pathogenesis that results in severe gastrointestinal complications. This study investigates the inhibitory potential of bioactive compounds derived from Brassica oleracea L., specifically targeting the CDTa subunit of the binary ...
Ariful Islam, Sumaiya Jahan Supti, Faria Tasnim, Md. Zahid Hasan, Mst Naharina Nuryay, Nabida Tabassum, Maysha Fahmeda Priota, Md. Jan Sadur Rahman Moon, Taha Alqahtani, Magdi E. A. Zaki, Subir Sarker, Md. Eram Hosen, Chandrabose Selvaraj   +12 more
wiley   +1 more source

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis

, 2017
Background Fidaxomicin is a narrow spectrum macrocyclic antibiotic used for the treatment of Clostridium difficileinfection (CDI). The objective of this study is to compare the recurrence and mortality rates of patients with CDI who ...
Luis A Marcos, Robert Chow, Teresa Khoo, Melinda Monteforte, Zachary Fleischner   +4 more
core   +1 more source